IP Library Granted Patent US 10,632,147
Granted Patent B2
US 10,632,147 · App. 15/966,886 · Granted Apr 28, 2020

Methods and compositions for treating inflammatory disorders

Inventors: Claire Sampson (Fort Worth, TX); Mark Sampson (Fort Worth, TX); Svetlana Panicheva (Fort Worth, TX); Cary Schockemoehl (Fort Worth, TX)
Assignee: URGO US, INC.
A61K33/20A61K45/06A61K9/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,632,147
App. No.
15/966,886
Granted
Apr 28, 2020
Kind
B2
Abstract

The present invention provides methods for treating conditions that involve infection and/or inflammation, including acute and chronic inflammation, as well as delayed-type and immediate-type hypersensitivity. The invention in various embodiments provides methods for treating microbial infection and the associated inflammatory response, as well methods for treating inflammatory conditions that spawn or are susceptible to secondary microbial infection. Further, the invention provides methods for treating inflammation, such as chronic inflammation, without any associated microbial infection.

Claims (13)

1. A method for treating a patient having a nasal condition comprising a microbial infection and chronic inflammation, the method comprising:

administering a hypochlorous acid formulation to an affected area of the nose of the patient, wherein the hypochlorous acid formulation has at least 250 ppm of available free chlorine and is at least 90% hypochlorous acid relative to the total concentration of hypochlorous acid, hypochlorite, and molecular chlorine.

2. The method of claim 1 , wherein the chronic inflammation is a delayed-type hypersensitivity.

3. The method of claim 1 , wherein the chronic inflammation is an immediate-type hypersensitivity.

4. The method of claim 1 , wherein the condition is rhinitis, rhinorrhea, nasal congestion, or sinusitis.

5. The method of claim 4 , wherein the hypochlorous acid formulation is delivered intranasally.

6. The method of claim 5 , wherein the hypochlorous acid formulation comprises a nasal spray, nasal rinse, nasal cream or nasal gel.

7. The method of claim 1 , further comprising additionally administering an effective amount of an antibiotic to treat the microbial infection.

8. The method of claim 1 , wherein the hypochlorous acid formulation has a pH of from 5 to 6.5.

9. The method of claim 1 , wherein the hypochlorous acid formulation has an available free chlorine content of from 250 ppm to 1000 ppm.

10. The method of claim 1 , wherein the hypochlorous acid formulation has an available free chlorine content of from 250 ppm to 400 ppm.

11. The method of claim 1 , wherein the hypochlorous acid formulation is administered to the affected area one to four times daily.

12. The method of claim 1 , wherein the condition is allergic rhinitis.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2020
From: SAMPSON, CLAIRE; SAMPSON, MARK; PANICHEVA, SVETLANA; SCHOCKEMOEHL, CARY
To: PURICORE, INC.
Reel/Frame 051467/0307 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2019
From: REALM THERAPEUTICS, INC.
To: URGO US, INC.
Reel/Frame 049405/0191 →
CHANGE OF NAME Recorded Jan 31, 2019
From: PURICORE, INC.
To: REALM THERAPEUTICS, INC.
Reel/Frame 048204/0629 →